Neurocrine Biosciences
NBIX
#1370
Rank
A$23.30 B
Marketcap
A$230.27
Share price
-1.97%
Change (1 day)
8.24%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): A$10.14

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is A$10.46. In 2025 the company made an earnings per share (EPS) of A$7.23 an increase over its 2024 EPS that were of A$5.07.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$10.1440.2%
2025A$7.2342.6%
2024A$5.0733.07%
2023A$3.8157.76%
2022A$2.4269.47%
2021A$1.43-78.21%
2020A$6.54990%
2019A$0.6081.82%
2018A$0.33-113.5%
2017A-$2.450.62%
2016A-$2.4357.28%
2015A-$1.5525.61%
2014A-$1.2318.84%
2013A-$1.04-1085.71%
2012A$0.11

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
A$1.07-89.81%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
A$8.78-16.05%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
A$46.34 343.20%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
A-$0.30-102.87%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
A-$3.05-129.12%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
A$7.77-25.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
A-$11.33-208.32%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
A$2.29-78.06%๐Ÿ‡ฌ๐Ÿ‡ง UK